ValoRization of Dairy Sidestreams to Fight Calcium dEficits iN Postmenopausal Women

NCT ID: NCT04836637

Last Updated: 2023-10-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

420 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-05-17

Study Completion Date

2023-07-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to investigate the effects of 12-months supplementation with calcium-enriched permeate, taken alone or in conjunction with inulin, on changes in markers of bone formation and resorption and in bone mass density (BMD) in apparently healthy postmenopausal women compared with calcium-carbonate or maltodextrin supplementation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will include an information visit, a randomization visit, a month 3 visit and a final visit at month 12. Besides, two visits at month 6 and 9 for dispensing of trial products. Outcome parameters will be measured using blood samples obtained at the randomization visit, the month 3 visit and at the final visit at month 12. Outcome parameters will moreover be analyzed based on DXA scan obtained at the randomization visit and at the final visit at 12 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoporosis, Postmenopausal

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Product with placebo (no calcium supplementation).

Maltodextrin with 0 mg calcium in capsules and sachets consumed orally daily for one year.

Group Type PLACEBO_COMPARATOR

Maltodextrin

Intervention Type DIETARY_SUPPLEMENT

Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.

Product with calcium-carbonate

800 mg calcium as calcium-carbonate in capsules and sachets consumed orally daily for one year.

Group Type ACTIVE_COMPARATOR

Calcium-carbonate

Intervention Type DIETARY_SUPPLEMENT

Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.

Product with calcium-enriched permeate "Capolac"

800 mg of calcium from calcium-enriched permeate in capsules and sachets consumed orally daily for one year.

Group Type EXPERIMENTAL

Calcium-enriched permeate

Intervention Type DIETARY_SUPPLEMENT

Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.

Product with calcium-enriched permeate "Capolac" and Inulin

800 mg of calcium from calcium-enriched permeate and 12 g inulin in capsules and sachets consumed orally daily for one year.

Group Type EXPERIMENTAL

Calcium-enriched permeate with Inulin

Intervention Type DIETARY_SUPPLEMENT

Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Maltodextrin

Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.

Intervention Type DIETARY_SUPPLEMENT

Calcium-carbonate

Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.

Intervention Type DIETARY_SUPPLEMENT

Calcium-enriched permeate

Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.

Intervention Type DIETARY_SUPPLEMENT

Calcium-enriched permeate with Inulin

Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Capolac Capolac Inulin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject is between 45 years and 65 years of age by the time of inclusion.
* Subject has been menopausal for at least 1 year, defined as 12 months after last bleeding and up to 10 years.
* Subject is Caucasian.
* Has a BMI below 35.0.
* Holder of a computer.
* Has a sufficient vitamin D status (plasma 25OHD concentration \> 50 nmol/L).
* Subject is willing and able to provide written informed consent prior to participation.

Exclusion Criteria

* Subject taking supplements or medicine that affects calcium and bone metabolism e.g. diuretics or hormone replacement therapy evaluated by the investigator.
* Intake of antibiotics in the last 3 months before enrollment.
* Subject with an osteoporosis diagnosis or history of osteoporotic fractures.
* Presence of renal, gastrointestinal, hepatic or endocrinological diseases.
* Subject with any serious illness or history of cancer within the past 5 years (except adequately-treated localized basal cell skin cancer or in situ uterine cervical cancer).
* Known or suspected abuse of alcohol or recreational drugs.
* Known milk allergy.
* Known or suspected hypersensitivity to trial products or related products.
* Blood donation except from the donation in this study.
* Subject where it is not possible to obtain sufficient data.
Minimum Eligible Age

45 Years

Maximum Eligible Age

75 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Zealand University Hospital

OTHER

Sponsor Role collaborator

University of Copenhagen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Inge Tetens

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mette F Hitz, Doctor

Role: PRINCIPAL_INVESTIGATOR

Zealand University Hospital, Køge

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Copenhagen University, Department of Nutrition, Exercise and Sports, Section for Clinical and Preventive Nutrition

Copenhagen, Frederiksberg, Denmark

Site Status

Zealand University Hospital

Køge, , Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

M236

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.